Status:
ACTIVE_NOT_RECRUITING
Evaluation of the Prognostic Impact of Decreased Serum beta2 Microglobulin in the First Year of Follow-up of Myeloproliferative Neoplasia (PRODIGE)
Lead Sponsor:
University Hospital, Brest
Conditions:
Myeloproliferative Neoplasm
Eligibility:
All Genders
18+ years
Brief Summary
50 patients with a diagnosis of MPN will have an assessment of b2microglobuline at diagnosis and after 1 year. b2mic value decrease will be compared to treatment response.
Eligibility Criteria
Inclusion
- MPN patient diagnosed at one of the participating centers
- over 18 yo
Exclusion
- Not able to consent
Key Trial Info
Start Date :
August 12 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 31 2026
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06553638
Start Date
August 12 2024
End Date
May 31 2026
Last Update
August 14 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chu Brest
Brest, France, 29609